A few days ago, the US financial institution Bank of America Merrill Lynch and GenomeWeb jointly conducted a new survey on the NGS market. The results show that demand for NGS is still strong, and the market for NGS is expanding beyond the traditional core academic and government markets.
The survey, conducted in March this year, surveyed more than 300 academic, government-supported laboratories, pharmaceutical and biotechnology companies, CRO companies, and hospitals and medical centers. Of the 285 respondents, 60% of the respondents had a laboratory or institution with an NGS system, and another 7% said they plan to purchase NGS instruments within the next 12 months.
It is worth noting that nearly half of the 182 existing users plan to purchase the NGS system again next year, indicating that sequencing demand continues to grow. Most respondents plan to purchase large high-throughput sequencers or desktop NGS platforms, while a few are interested in Oxford Nanopore Technologies' nanopore sequencers.
Respondents most often refer to Illumina's sequencing system, which they most want to purchase is the HiSeq 2500/3000/4000 instrument, followed by the NovaSeq 5000/6000 and HiSeq X. Analyst Derik de Bruin said respondents were particularly enthusiastic about other types of sequencers other than NovaSeq, which also indicates that NovaSeq will not completely take over the high-throughput sequencing market in the future. The survey also found that one-third of users planning to purchase NovaSeq also wanted to retain existing sequencing instruments.
In addition, although most of the people planning to purchase NGS instruments are in academia or government-related institutions, laboratories in other industries also have high-throughput sequencers, including pharmaceutical and biotechnology laboratories, CRO companies, and genomic services. Providers as well as hospitals and medical centers. Analysts believe that this expansion to non-academic and government end markets is a positive indicator, indicating that market construction is making progress and contributing to the further expansion of the entire sequencing market.
In addition to purchasing new sequencing systems, most laboratories plan to invest more in bioinformatics. Nearly 60% of the 140 respondents indicated that they expect to increase bioinformatics spending in the next 12 months. A large proportion of these respondents indicated that this additional expenditure will be used to recruit bioinformatics personnel.
The survey also found that, contrary to past analysis, the overcapacity in the sequencing market is not serious. Only 35% of the 166 respondents used their sequencers with less than 40% of their operational capabilities. About two-thirds of users expect to increase the capacity of the sequencer in the next 12 months.
Guangzhou Zhongzhinan Supply Chain Co.,Ltd. , https://www.gzzhongzhinan.com